EffRx Pharmaceuticals
Manufacturing · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Wolleraustrasse 41b, Freienbach, Schwyz,...Phone Number
+41 445037860Website
www.effrx.comRevenue
$5.5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About EffRx Pharmaceuticals
EffRx Pharmaceuticals SA is a commercial-stage biopharmaceutical company dedicated to the late-stage development and commercialization of prescription medications for rare endocrine and metabolic disorders, as well as musculoskeletal diseases. The company focuses on niche therapeutics in Europe, particularly addressing unmet medical needs in patients suffering from conditions such as osteoporosis, adrenal insufficiency, and various rare diseases. EffRx aims to improve the health and quality of life for patients through innovative treatments and strategic partnerships. Their flagship product, Binosto, is the first and only buffered solution for the treatment of osteoporosis.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is EffRx Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once EffRx Pharmaceuticals has new funding data
EffRx Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when EffRx Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if EffRx Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at EffRx Pharmaceuticals
Earning: See what the market has to say on EffRx Pharmaceuticals recently announced quarterly report
Check if EffRx Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if EffRx Pharmaceuticals is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
EffRx Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
EffRx Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about EffRx Pharmaceuticals.
EffRx Pharmaceuticals financials insights
Gather financial insights about EffRx Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$2.3M
EffRx Pharmaceuticals Tech Stack
A closer look at the technologies used by EffRx Pharmaceuticals
EffRx Pharmaceuticals News & Media
Abiogen Pharma Acquires 97,09% Stake in EffRx Pharmaceuticals
Abiogen Pharma, a Pisa, Italy-based company focused on osteoarticular and bone metabolism diseases, acquired a 97,09% stake in EffRx Pharmaceuticals, a Freienbach, Switzerland-based company that develops and markets prescription drugs targeted in particular to musculoskeletal and rare pathologies on European and international markets. The amount of the deal was not disclosed. With the acquisition, Abiogen […] The post Abiogen Pharma Acquires 97,09% Stake in EffRx Pharmaceuticals appeared first oABIOGEN PHARMA COMPLETES THE ACQUISITION OF EFFRX
PISA, Italy, May 29, 2023 /PRNewswire/ -- Abiogen Pharma S.p.A., Italian leading company in the field of osteoarticular and bone metabolism diseases, is pleased to announce the acquisition of a 97,09% stake in EffRx Pharmaceuticals SA, a Swiss company that develops and markets...World Orphan Drug Alliance - combining forces to reach patients with rare diseases across the globe
World Orphan Drug Alliance (WODA) is a new global alliance of full-service regional distributors for orphan drugs. WODA covers 68 countries on 4 continents. There are more than 64 million potential patients with rare diseases in the WODA regions. ZURICH, MOSCOW, SAO PAULO, DUBAI, UAE and...EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody® in Switzerland
FREIENBACH, Switzerland--(BUSINESS WIRE)-- #Alkindi--EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, for the registration and commercialization of Efmody® as treatment for congenital adrenal hyperplasia (CAH) in Switzerland. Under the terms of the agreement EffRx has received the exclusive rights to register and commerc
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding EffRx Pharmaceuticals
Sign Up For FreeTo access detailed company insights
EffRx Pharmaceuticals SA is a commercial-stage biopharmaceutical company dedicated to the late-stage development and commercialization of prescription medications for rare endocrine and metabolic disorders, as well as musculoskeletal diseases. The company focuses on niche therapeutics in Europe, particularly addressing unmet medical needs in patien... Read More
